Supplement therapy with apelin for improving the TSH level and lipid disorders in PTU‐induced hypothyroid rats. (11th May 2021)

• Record Type: Journal Article
• Authors: Badavi, Mohammad; Grootveld, Martin; Jafari, Fereshteh; Dianat, Mahin; Faraji Shahrivar, Farzaneh
• Is Part Of: Biotechnology and applied biochemistry. Volume 69:Number 2(2022)
• Page Start: 668
• Page End: 675
• Publication Date: 2021-05-11
• Subjects: apelin -- body weight -- hypothyroid -- lipid profile -- rat -- thyroid‐stimulating hormone -- thyroxine; Biotechnology -- Periodicals; Biochemical engineering -- Periodicals; Biochemistry -- Periodicals; Biochemistry -- Periodicals; Genetic Techniques -- Periodicals; Microbiological Techniques -- Periodicals; 660.6
• DOI: 10.1002/bab.2142
• Languages: English
• ISSNs: 0885-4513

Abstract

Abstract: Hyperlipidemia is a common metabolic disorder in the general population, which may arise in hypothyroidism. Apelin is an endogenous ligand that acts as an adiponectin, and is involved in energy storage and metabolism. This study evaluated the effects of apelin administration per se or in combination with T4 on the serum level of thyroid‐stimulating hormone (TSH), body weight, and lipid profile, along with the serum level of apelin, and its mRNA expression in heart, in 6‐propyl‐2‐thiouracil (PTU)‐induced hypothyroid rats. Male Wistar rats were assigned to five different groups: control, H (hypothyroid), H+A, H+T, and H+A+T. All groups except the control one received PTU (0.05%) in the drinking water for 6 weeks. In addition to PTU, the H+A, H+T, and H+A+T groups received apelin (200 μg/kg/day, i.p.), l ‐thyroxin (T4) (20 μg/kg/day, via gavage tube), and apelin+T4 during the last 14 days of the trial, respectively. A combined application of T4 and apelin in the H+A+T group effectively diminished mean TSH level, low‐density‐lipoprotein cholesterol/high‐density‐lipoprotein cholesterol ratio, and atherogenic index in these animals when compared with these values for the H group. Coadministration of apelin with T4 may offer valuable therapeutic benefits, specifically lowering blood plasma TSH, lipid disorder, and atherosclerosis biomarkers in PTU‐induced hypothyroid rats.